Nugenerex Immuno-Oncology Equity 2024

Nugenerex Immuno-Oncology Aktienanalyse

What does Nugenerex Immuno-Oncology do?

Nugenerex Immuno-Oncology Inc is an emerging company in cancer research and treatment. It was founded in 2003 by Dr. William J. Garner and is headquartered in San Diego, California. The origins of Nugenerex Immuno-Oncology lie in the exploration of RNA interference (RNAi) and the development of therapeutics for the treatment of cancer and other diseases. In 2006, the company made a groundbreaking discovery by developing a novel technology called "Blank Gene Therapy," which has the potential to revolutionize cancer treatment. Nugenerex Immuno-Oncology is an innovative biotechnology company focused on developing cancer treatments based on the patient's own immune system. The company has a division for cancer research and development and a division for medical services, combining scientific expertise with a global presence. In its research and development division, Nugenerex Immuno-Oncology focuses on developing novel immunological therapies based on "Blank Gene Therapy." These therapies aim to stimulate the patient's immune system to recognize and destroy cancerous cells. In addition to research and development, the company also offers medical services. The medical services division provides patients and healthcare providers worldwide with access to the latest cancer treatments and clinical trials. By collaborating with doctors and hospitals worldwide, patients gain access to innovative cancer treatments tailored to their specific case. The company has several products in development, including a novel immunotherapeutic called "Enrichin." It is based on "Blank Gene Therapy" and aims to stimulate the patient's immune system to recognize and destroy tumor-like cells. Additionally, the company is working on the development of antibody therapeutics and oncolytic viruses to destroy cancer cells. Nugenerex Immuno-Oncology has also formed a partnership with a leading pharmaceutical company to develop therapeutics for multiple sclerosis and other autoimmune diseases. In summary, Nugenerex Immuno-Oncology is an emerging company in cancer research and treatment, focusing on novel immunological therapies. With its products, services, and global presence, it aims to improve the lives of cancer patients worldwide. Nugenerex Immuno-Oncology ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Nugenerex Immuno-Oncology's Equity

Nugenerex Immuno-Oncology's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Nugenerex Immuno-Oncology's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Nugenerex Immuno-Oncology's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Nugenerex Immuno-Oncology's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Nugenerex Immuno-Oncology’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Nugenerex Immuno-Oncology stock

What is the equity of Nugenerex Immuno-Oncology this year?

Nugenerex Immuno-Oncology has equity of 0 USD this year.

What was the equity of Nugenerex Immuno-Oncology compared to the previous year?

The equity of Nugenerex Immuno-Oncology has increased/decreased by 0% decreased compared to the previous year.

What impact does a high equity have on investors of Nugenerex Immuno-Oncology?

A high equity is advantageous for investors of Nugenerex Immuno-Oncology as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Nugenerex Immuno-Oncology?

A low equity can be a risk for investors of Nugenerex Immuno-Oncology, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Nugenerex Immuno-Oncology affect the company?

An increase in equity of Nugenerex Immuno-Oncology can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Nugenerex Immuno-Oncology affect the company?

A reduction in equity of Nugenerex Immuno-Oncology can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Nugenerex Immuno-Oncology?

Some factors that can affect the equity of Nugenerex Immuno-Oncology include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Nugenerex Immuno-Oncology so important for investors?

The equity of Nugenerex Immuno-Oncology is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Nugenerex Immuno-Oncology take to change the equity?

To change equity, Nugenerex Immuno-Oncology can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Nugenerex Immuno-Oncology pay?

Over the past 12 months, Nugenerex Immuno-Oncology paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Nugenerex Immuno-Oncology is expected to pay a dividend of 0 USD.

What is the dividend yield of Nugenerex Immuno-Oncology?

The current dividend yield of Nugenerex Immuno-Oncology is .

When does Nugenerex Immuno-Oncology pay dividends?

Nugenerex Immuno-Oncology pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Nugenerex Immuno-Oncology?

Nugenerex Immuno-Oncology paid dividends every year for the past 0 years.

What is the dividend of Nugenerex Immuno-Oncology?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Nugenerex Immuno-Oncology located?

Nugenerex Immuno-Oncology is assigned to the '-' sector.

Wann musste ich die Aktien von Nugenerex Immuno-Oncology kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Nugenerex Immuno-Oncology from 9/30/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/30/2024.

When did Nugenerex Immuno-Oncology pay the last dividend?

The last dividend was paid out on 9/30/2024.

What was the dividend of Nugenerex Immuno-Oncology in the year 2023?

In the year 2023, Nugenerex Immuno-Oncology distributed 0 USD as dividends.

In which currency does Nugenerex Immuno-Oncology pay out the dividend?

The dividends of Nugenerex Immuno-Oncology are distributed in USD.